Leukaemia and L...
Posted by

Cancer Research UK and Leukaemia & Lymphoma Research team up to boost blood cancer trials

Leukaemia and L...
Posted by
27 Oct 2014

Cancer Research UK, with its commercial arm Cancer Research Technology, and Leukaemia & Lymphoma Research today (Monday) announce they have signed a deal to jointly fund early phase clinical trials of experimental drugs for patients with blood cancers.

This collaboration will increase support for trials of promising new treatments for blood cancers – leukaemias, lymphomas and myeloma – which affect around 30,000 people every year in the UK.

Leukaemia & Lymphoma Research will provide access to promising new treatments that are being researched by its scientists, as well as financial support for Cancer Research UK to develop these therapies through preclinical, and early Phase I and Phase II clinical development.

The trials will be managed and run by Cancer Research UK’s Centre for Drug Development through the Experimental Cancer Medicine Centre (ECMC) network, an initiative funded by Cancer Research UK and the UK’s four Health Departments, at hospitals across the country.

Cancer Research Technology will be responsible for the further clinical and commercial development of joint projects, ensuring that both charities receive a proportion of revenues from any drugs that ultimately reach the market. The agreement will initially last five years, with up to five trials anticipated to be funded in that time.

Professor Chris Bunce, research director at Leukaemia & Lymphoma Research, said: “We are at an exciting period in blood cancer research, with our scientists identifying more treatment targets and developing more drugs than ever before. The infrastructure and know-how exchanged by working together with Cancer Research UK will enable this initiative to give patients access to potentially life-saving breakthroughs sooner.

“There is an urgent need for new blood cancer drugs, as many patients cannot tolerate or do not respond to traditional treatment options like chemotherapy.”

Dr Nigel Blackburn, director of Cancer Research UK’s Centre for Drug Development, said: “Bringing together Cancer Research UK’s cutting-edge facilities and expertise, with Leukaemia & Lymphoma Research’s high quality research is an exciting prospect that we hope will bring promising new treatments to patients with blood cancer sooner.

“As the world’s largest charity dedicated to cancer research, we hope this will pave the way for further strategic partnerships with other charities who are interested in working together to speed up the translation of today’s scientific discoveries into future cancer treatments.”

Comments

29.10.2014

This is absolutely amazing news which will have an enormous impact for patients. It's great that we're working together with Cancer Research on this as it's through collaborating resources and supporting each other that we'll ultimately beat blood cancer.

With new developments in treatments being made all the time and the new 5 year plan proposals promising to concentrate on faster diagnosis and more uniform treatments and a more patient centric approach to care this is a very exciting time in which we can do a great deal to help blood cancer patients and their families.

Anonymous
06.11.2014

This is wonderful news. Thank you to all those who have worked so hard for this in all manner of ways from researchers to fundraisers and all those involved in the trials. Congratulations to Jack too!!

Anonymous
06.11.2014

Can I say a really big thank you to all who have supported this wonderful group . I myself have blood cancer so I speak from experience not all our conventional drugs suit us.. I was offered a trial drug ruxolitinib ,in the Majic trial at guys and st Thomases in London .i am now so much better every day ,it turned my world around ..made me feel normal again ..thank you so much ..

Anonymous
07.11.2014

Thanks to all three organisations for your work. My two year old grandson has AML. We are grateful for this research, both for his sake and all blood cancer sufferers.